Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors
Status:
Active, not recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of
DS-6051b in Japanese subjects with advanced solid malignant tumors harboring either a ROS1 or
NTRK fusion gene.